The results and interpretation of the meta-analysis by Wandel and colleagues of the effects of glucosamine and chondroitin on osteoarthritis depend on the trials analysed and the thresholds defined as clinically relevant.1 The criteria for the selection of trials is questionable; the European Medicines Agency recommends evaluating the analgesic effect of slow acting drugs for osteoarthritis after at least six months of treatment, and the structural effect after two years. …